Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial
Using data from a large dataset people who smoke in the United States, it is possible to predict an individual's likelihood of psychiatric and nonpsychiatric AEs during smoking cessation treatment prior to initiating treatment. These predictive models provide a starting point for future work addressing how best to modify and integrate such clinical decision support algorithms into treatment for smoking cessation.
Authors
- Rachel L. Tomko (ORCID: https://orcid.org/0000-0002-6961-4399)
- Jennifer Dahne (ORCID: https://orcid.org/0000-0001-7297-9420)
- Daniel Hashemi (ORCID: https://orcid.org/0000-0002-1783-8905)
- Kevin M. Gray (ORCID: https://orcid.org/0000-0003-4503-7395)
- Bethany J. Wolf (ORCID: https://orcid.org/0000-0002-7124-5158)
Institutions
- Harvard University (US)
- Medical University of South Carolina (US)
- MUSC Hollings Cancer Center (US)
Publication Details
- Journal
- Nicotine & Tobacco Research
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/ntr/ntae290
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- National Institutes of Health
- National Cancer Institute